Login to Your Account



Gensight gene therapy targets rapid blindness of LHON in pivotal trials

By Jennifer Boggs
Managing Editor

Monday, February 29, 2016

Gensight Biologics SA launched a pair of phase III studies aimed at testing gene therapy candidate GS010's ability to preserve and restore vision in patients with blindness-causing Leber's hereditary optic neuropathy (LHON), a disease in which "time is of the essence," said Chairman and CEO Bernard Gilly.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription